Boundless Bio Announces Departure of Chief Financial Officer
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced the departure of CFO Jami Rubin for personal reasons. The company does not plan to hire a successor CFO immediately. David Hinkle, Senior VP of Finance and Controller, will assume responsibility for Finance operations and the roles of principal financial and accounting officer.
CEO Zachary Hornby expressed gratitude for Rubin's contributions, particularly in the company's successful IPO and corporate strategy refinement. Rubin stated her pride in Boundless Bio's accomplishments and confidence in the company's future success, citing ongoing clinical trials for lead programs and a strong balance sheet to support their advancement.
Boundless Bio (Nasdaq: BOLD), un'azienda oncologica in fase clinica focalizzata sulla biologia del DNA extracromosomico (ecDNA) per il trattamento dei tumori con amplificazione degli oncogeni, ha annunciato le dimissioni del CFO Jami Rubin per motivi personali. L'azienda non prevede di assumere un CFO successore immediatamente. David Hinkle, VP Senior delle Finanze e Controller, assumerà la responsabilità delle operazioni finanziarie e dei ruoli di principale responsabile finanziario e contabile.
Il CEO Zachary Hornby ha espresso gratitudine per i contributi di Rubin, in particolare per il successo dell'IPO dell'azienda e il perfezionamento della strategia aziendale. Rubin ha dichiarato di essere orgogliosa dei successi di Boundless Bio e di avere fiducia nel futuro successo dell'azienda, citando gli studi clinici in corso per i programmi principali e un bilancio solido a sostegno del loro avanzamento.
Boundless Bio (Nasdaq: BOLD), una empresa de oncología en etapa clínica centrada en la biología del ADN extracromosómico (ecDNA) para tratar cánceres amplificados por oncogenes, anunció la salida de la CFO Jami Rubin por motivos personales. La compañía no planea contratar un CFO sucesor de inmediato. David Hinkle, VP Senior de Finanzas y Controlador, asumirá la responsabilidad de las operaciones financieras y los roles de principal responsable financiero y contable.
El CEO Zachary Hornby expresó su agradecimiento por las contribuciones de Rubin, particularmente en la exitosa IPO de la empresa y en el perfeccionamiento de la estrategia corporativa. Rubin afirmó sentirse orgullosa de los logros de Boundless Bio y tener confianza en el éxito futuro de la compañía, citando ensayos clínicos en curso para los programas principales y un balance sólido para apoyar su avance.
Boundless Bio (Nasdaq: BOLD)는 온코겐 증폭 암 치료를 위해 엑스트라 크로모솜 DNA(ecDNA) 생물학에 초점을 맞춘 임상 단계의 암 치료 회사로, CFO Jami Rubin이 개인적인 사유로 떠났다고 발표했습니다. 회사는 즉시 후임 CFO를 고용할 계획이 없습니다. 재무 고위 부사장인 David Hinkle이 재무 운영과 주요 재무 및 회계 책임자의 역할을 맡게 됩니다.
CEO Zachary Hornby는 Rubin의 기여, 특히 회사의 성공적인 IPO와 기업 전략 개선에 대한 감사의 뜻을 전했습니다. Rubin은 Boundless Bio의 성과에 자부심을 느끼며 회사의 미래 성공에 대한 확신을 표명하며, 주요 프로그램의 진행 중인 임상 시험과 그 발전을 지원하는 강력한 재무 상태를 언급했습니다.
Boundless Bio (Nasdaq: BOLD), une entreprise d'oncologie en phase clinique axée sur la biologie de l'ADN extracromosomique (ecDNA) pour le traitement des cancers amplifiés par des oncogènes, a annoncé le départ de la CFO Jami Rubin pour des raisons personnelles. L'entreprise ne prévoit pas d'embaucher immédiatement un CFO successeur. David Hinkle, VP senior des finances et contrôleur, assumera la responsabilité des opérations financières ainsi que les rôles de principal responsable financier et comptable.
Le PDG Zachary Hornby a exprimé sa gratitude pour les contributions de Rubin, notamment pour le succès de l'introduction en bourse de l'entreprise et le perfectionnement de la stratégie d'entreprise. Rubin a déclaré qu'elle était fière des réalisations de Boundless Bio et qu'elle avait confiance dans le succès futur de l'entreprise, citant les essais cliniques en cours pour les programmes phares et un bilan solide pour soutenir leur avancement.
Boundless Bio (Nasdaq: BOLD), ein in der klinischen Phase befindlichesonkologisches Unternehmen, das sich auf die Biologie von extrachromosomaler DNA (ecDNA) zur Behandlung von onkogen-amplifizierten Krebserkrankungen konzentriert, gab den Rücktritt von CFO Jami Rubin aus persönlichen Gründen bekannt. Das Unternehmen plant nicht, sofort einen Nachfolger für den CFO einzustellen. David Hinkle, Senior VP für Finanzen und Controller, wird die Verantwortung für die Finanzoperationen und die Funktionen des Hauptfinanz- und Rechnungswesens übernehmen.
CEO Zachary Hornby drückte seine Dankbarkeit für Rubins Beiträge aus, insbesondere für den erfolgreichen Börsengang des Unternehmens und die Verfeinerung der Unternehmensstrategie. Rubin erklärte, dass sie stolz auf die Erfolge von Boundless Bio sei und Vertrauen in den zukünftigen Erfolg des Unternehmens habe, indem sie die laufenden klinischen Studien der Hauptprogramme und eine starke Bilanz zur Unterstützung deren Fortschritts anführte.
- Successful IPO completed under departing CFO's leadership
- Strong balance sheet to support ongoing clinical trials
- Seamless transition of financial responsibilities to existing Senior VP of Finance
- Departure of Chief Financial Officer
- No immediate plans to hire a successor CFO
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does not plan to hire a successor CFO at this time; David Hinkle, Senior Vice President, Finance and Controller, will maintain responsibility for the company’s Finance operations and assume the roles of principal financial and accounting officer.
“On behalf of the company and Board, I want to extend my sincerest gratitude to Jami for her many contributions during her tenure at Boundless, including her leadership in the success of our IPO and the refinement of our corporate strategy,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Thanks to Jami’s contributions, Boundless is in a strong position for the future and we wish her all the best.”
“It has been an honor to serve in this position, and I take great pride in what we have accomplished at Boundless on our journey to become a leader in developing drugs to treat patients with oncogene amplified cancers,” said Ms. Rubin. “A hallmark of my time at Boundless has been collaborating with such a talented team and supportive Board. With the clinical trials underway for our lead programs and a balance sheet that supports their continued advancement, I am confident that Boundless is positioned for success.”
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than
For more information, visit www.boundlessbio.com. Follow us on LinkedIn and X.
Forward-Looking Statements
Boundless Bio cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include but are not limited to: the strength of our position and the potential for success; and the sufficiency of our team and our balance sheet to support advancement of our clinical pipeline. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: we are early in our development efforts and our approach to discover and develop ecDTx directed against ecDNA in oncogene amplified cancers is novel and unproven; results from preclinical studies or early clinical trials not necessarily being predictive of future results; potential delays in the commencement, enrollment, data readouts or completion of clinical trials or preclinical studies; unfavorable results from clinical trials or preclinical studies; unexpected adverse side effects or inadequate efficacy of our ecDTx that may limit their development, regulatory approval, and/or commercialization; regulatory developments in the United States and foreign countries; we may use our capital resources sooner than we expect; any adverse impacts resulting from the departure of the Chief Financial Officer; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our quarterly report on Form 10-Q for the quarter ended June 30, 2024 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
Why did Boundless Bio's CFO Jami Rubin step down?
Who will take over the financial responsibilities at Boundless Bio (BOLD) after the CFO's departure?
What major achievements did Jami Rubin contribute to during her tenure as CFO of Boundless Bio (BOLD)?
What is the current financial position of Boundless Bio (BOLD) following the CFO's departure?
